Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone + X
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Pola-R-CHP-X is an investigational, genotype-guided combination regimen being evaluated in the Phase 3 GUIDANCE 05 trial for the treatment of previously untreated double-expression diffuse large B-cell lymphoma (DLBCL). The regimen builds upon the Pola-R-CHP backbone (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) by adding a personalized targeted agent ('X') based on the patient's genetic subtype. The 'X' component is selected following initial treatment and ctDNA monitoring: acalabrutinib (a BTK inhibitor) for MCD/BN2/N1-like subtypes, lenalidomide (an immunomodulatory agent) for EZB or ST2-like subtypes, decitabine (a hypomethylating agent) for TP53-mutated subtypes, or a PD-1 inhibitor for C1 subtypes. This precision medicine approach aims to improve outcomes in high-risk DEL patients by tailoring therapy to the underlying molecular drivers of the disease.
- Other names
- Polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone + X-Ruijin Hospital-diffuse large B-cell lymphomaPola-R-CHP plus genotype-guided targeted agents
02
Targets
TUBB (Tubulin (alpha and beta subunits))B-cell antigen receptor complex-associated protein beta chainGR (Glucocorticoid receptor)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone + X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone + X.